My guess is that if everyone believes that Momenta's formulation is fully equivalent to Lovenox in terms of both active and inactive ingredients, then there is no particular perceived advantage to an AG versus just discounting Lovenox. If an appreciable number of people are concerned with potential differences in patient response, then an AG might be in the cards.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.